Last Updated: November 10, 2026

Details for Patent: 11,925,620

« Back to Dashboard


Which drugs does patent 11,925,620 protect, and when does it expire?

Patent 11,925,620 protects OGSIVEO and is included in one NDA.

This patent has eighty patent family members in twenty-nine countries.

Summary for Patent: 11,925,620
Title:Treatments with nirogacestat
Abstract:The present disclosure relates to improved methods of treatment with nirogacestat.
Inventor(s):Allison Lim, Shinta CHENG, Todd Webster SHEARER, Rex WILLIAMS, Kristin Patterson
Assignee: SpringWorks Therapeutics Inc
Application Number:US18/491,225
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 11,925,620

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Springworks OGSIVEO nirogacestat hydrobromide TABLET;ORAL 217677-001 Nov 27, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS ⤷  Start Trial
Springworks OGSIVEO nirogacestat hydrobromide TABLET;ORAL 217677-002 Apr 4, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS ⤷  Start Trial
Springworks OGSIVEO nirogacestat hydrobromide TABLET;ORAL 217677-003 Apr 4, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,925,620

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 4010322 ⤷  Start Trial CA 2026 00017 Denmark ⤷  Start Trial
European Patent Office 4010322 ⤷  Start Trial 301374 Netherlands ⤷  Start Trial
European Patent Office 4010322 ⤷  Start Trial C20260011 Finland ⤷  Start Trial
European Patent Office 4010322 ⤷  Start Trial LUC50046 Luxembourg ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.